Cargando…

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel

Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid increase in the use of coronary intervention procedures. Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy in patients treated with percutaneous coronary intervention. However, there are two is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Motovska, Zuzana, Widimsky, Petr
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686264/ https://www.ncbi.nlm.nih.gov/pubmed/19475783

Ejemplares similares

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Norgard, Nicholas B, et al.
Publicado: (2009)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention
por: Koyabu, Yota, et al.
Publicado: (2019)

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel
por: Geisler, Tobias, et al.
Publicado: (2015)

Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials
por: Almas, Talal, et al.
Publicado: (2022)

Serum Dickkopf-1 signaling and calcium deposition in aortic valve are significantly related to the presence of concomitant coronary atherosclerosis in patients with symptomatic calcified aortic stenosis
por: Motovska, Zuzana, et al.
Publicado: (2015)

Trends in outcomes of women with myocardial infarction undergoing primary angioplasty—Analysis of randomized trials
por: Motovska, Zuzana, et al.
Publicado: (2023)

Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe
por: Toušek, Petr, et al.
Publicado: (2022)

Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel
por: Hajsadeghi, Shokoufeh, et al.
Publicado: (2016)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
por: Larmore, Cynthia, et al.
Publicado: (2015)

Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy
por: Liu, Ping-Yen, et al.
Publicado: (2021)

Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic
por: Toušek, Petr, et al.
Publicado: (2020)

Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention
por: Sionova, Magdalena, et al.
Publicado: (2017)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Clopidogrel resistance "Live" – the risk of stent thrombosis should be evaluated before procedures
por: Motovska, Zuzana, et al.
Publicado: (2009)

Predictors allowing early discharge after interventional treatment of acute coronary syndrome patients
por: Bauer, Dávid, et al.
Publicado: (2022)

Effects of clopidogrel, prasugrel and ticagrelor on prevention of stent thrombosis in patients underwent percutaneous coronary intervention: A network meta‐analysis
por: Chen, Wenwen, et al.
Publicado: (2021)

Clinical review: Bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management
por: Doktorova, Magdalena, et al.
Publicado: (2013)

Erratum: Correction of Text in the Article “Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI”
por: Ki, You-Jeong, et al.
Publicado: (2022)

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
por: Pham, Son V, et al.
Publicado: (2010)

Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes
por: Yetgin, T., et al.
Publicado: (2013)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2018)

Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention
por: Shoukat, Sana, et al.
Publicado: (2010)

Management of Atrial Fibrillation in Patients Undergoing Percutaneous Coronary Intervention
por: Mirra, M, et al.
Publicado: (2014)

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions
por: Summaria, Francesco, et al.
Publicado: (2015)

Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
por: Bossard, Matthias, et al.
Publicado: (2017)

Randomized Comparison of the Platelet Inhibitory Efficacy between Low Dose Prasugrel and Standard Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention
por: Jin, Han-Young, et al.
Publicado: (2014)

Ticagrelor Versus Prasugrel for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
por: Yang, Hua, et al.
Publicado: (2018)

Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention
por: Chen, Zhongxiu, et al.
Publicado: (2021)

Neurotensin and Adverse Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention
por: Tscharre, Maximilian, et al.
Publicado: (2022)

Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
por: Kwak, Soongu, et al.
Publicado: (2019)

One-year efficacy and safety of routine prasugrel in patients with acute coronary syndromes treated with percutaneous coronary intervention: results of the prospective rijnmond collective cardiology research study
por: Yetgin, T., et al.
Publicado: (2018)

Lower Loading Dose of Prasugrel Compared with Conventional Loading Doses of Clopidogrel and Prasugrel in Korean Patients Undergoing Elective Coronary Angiography: A Randomized Controlled Study Evaluating Pharmacodynamic Efficacy
por: Lee, Dong Hyun, et al.
Publicado: (2014)

The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery
por: Moresco, Erich, et al.
Publicado: (2023)

Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8
por: Widimský, Petr, et al.
Publicado: (2008)

Comparison of 1-year clinical outcomes between prasugrel and ticagrelor versus clopidogrel in type 2 diabetes patients with acute myocardial infarction underwent successful percutaneous coronary intervention
por: Ahn, Kye Taek, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_blg4v1a8q133s9eatm5hit4b2b